{
    "nctId": "NCT03560310",
    "officialTitle": "Dual Antiplatelet Therapy With Ticagrelor and Acetylsalicylic Acid (ASA) vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patient With Acute Coronary Syndrome",
    "inclusionCriteria": "1. Written informed consent\n2. Age \u226518 years\n3. Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "1. Previously enrolled in this study (i.e. patient now at repeat encounter)\n2. Concomitant surgical procedure other than CABG\n3. Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux)\n4. Discharge from the operating hospital to an ICU at another hospital\n5. Pregnancy or lactation\n6. Known intolerance or contraindication to ticagrelor or ASA\n7. Any disorder that may interfere with drug absorption\n8. Any condition other than coronary artery disease with a life expectancy \\<12 months\n9. Known chronic liver disease, renal disease requiring dialysis or bleeding disorder\n10. Atrioventricular block II and III in patients without pacemaker\n11. Any other indication for dual antiplatelet therapy, i.e. recent stent implantation\n12. Debilitating stroke within 90 days before inclusion\n13. Previous intracranial bleeding\n14. Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus)\n15. Treatment with strong CYP3A4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir)\n16. Any condition that in the opinion of the investigator may interfere with adherence to trial protocol\n17. Participation in any other clinical trial evaluating investigational products at the time for enrollment in this study"
}